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1.0 Introduction
The  problem  of  varicose  veins  and  venous  ulcer  has  plagued  mankind  since 
prehistoric times. It is one of the many prices he had to pay for gaining an erect 
posture.  Though  we  have  achieved  cure  for  various  diseases,  till  now  no 
permanent cure has been found for venous insufficiency. Surgery has been the 
gold  standard  for  treating  chronic  venous  insufficiency.  The  challenge  for  the 
surgeon dealing with  varicose veins has always  been balancing a cosmetically 
acceptable  result  with  a  low  incidence  of  recurrence  and  complications. 
Increasingly  well-informed  patients  who  pressure  the  treating  surgeon  for 
cosmetically acceptable results in conjunction with expansion of minimally invasive 
techniques have  made  the  treatment  of  superficial  venous  reflux  and  varicose 
veins a rapidly evolving field.1  
New, minimally invasive techniques for the treatment of varicose veins including 
Radio  frequency  ablation  (RFA),  Endovenous  laser  therapy  (EVLT),  and 
Transilluminated  power  phlebectomy  (TIPP)  represent  effective  and  possibly 
superior alternatives to traditional saphenous vein stripping and stab avulsion of 
varicose veins. 1
Sclerotherapy can improve the cosmetic  appearance of  aberrant  blood vessels 
and greatly benefit  symptomatic veins by decreasing pain, burning, and cramps 
that many patients describe. Resolution of larger varicosities can improve the risk 
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of  further  venous  disease  sequelae.   Sclerotherapy  continues  to  be  the  gold 
standard in the treatment of lower extremity small vessel disease.2 The results of 
using  liquid  sclerosant  for  large  veins  were  poor.  After  the  use  of  foam 
sclerotherapy  for  large  veins,  the  recurrence  rates  have  come  down.  The 
availability of a simple method to create foam, proposed by Tessari,  has made 
foam sclerotherapy popular. The safety of foam sclerotherapy has been proven in 
large scale studies. The recurrence rates following foam sclerotherapy has been 
comparable to surgery. 
So  far  no  randomised  controlled  trial  has  compared  ultrasound  guided 
sclerotherapy with surgery. Therefore this study was carried out to compare the 
efficacy of foam sclerotherapy when compared to surgery.
12
2.0 Aims and Objectives
1. To  assess  the  obliteration  of  superficial  venous  system  following 
conventional surgery and ultrasound guided foam sclerotherapy at the end 
of 3 months.
2. To  compare  the  clinical  outcome  following  conventional  surgery  and 
ultrasound guided foam sclerotherapy at the end of 3 months.
3. To compare the cost  of  the conventional  surgery and ultrasound guided 
foam sclerotherapy for the treatment of chronic venous insufficiency.
13
3.0 Review of Literature
3.1 Background
Chronic  venous  insufficiency  is  a  very  common  problem  leading  to  recurrent 
ulceration in lower limbs and causes significant morbidity and increases healthcare 
costs.  Commonly  reported  symptoms  include  local  discomfort  over  varicosities 
(pain, burning discomfort, aching and itching), generalized lower limb symptoms 
(aching, heaviness, swelling and restless leg syndrome) and nocturnal cramps, as 
well as complaints about cosmetic appearance. Women are more prone to these 
symptoms due to hormonal influences.3 Swelling and night cramps are commonly 
reported  symptoms  of  varicose  veins  in  pregnancy.   There  is  little  correlation 
between symptoms of varicose veins and their extent or size on examination.
Though surgery has been the gold standard for the treatment of chronic venous 
insufficiency, it does have risk of recurrence and associated morbidity.  Recently 
many minimally invasive methods with lower morbidity and equally good results 
have been used. Of all the newer methods, ultrasound guided foam sclerotherapy 
is the cheapest and simplest method with good result. 
3.2 History
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Surgery is commonly used to treat 'main stem' varicose veins. Sclerotherapy has 
been used to treat varicose veins from as early as 1835 according to records from 
Massachusetts General Hospital. Chassaignac, who published a series of cases 
from  1853  injected  zinc  chloride  into  varicose  veins.4  Hobbs  gave  a  historical 
overview on the use of sclerotherapy and compression bandaging in the early part 
of the 20th century, starting in Paris with Linser (1911) and Sicard (1911).5
Orbach,6  proposed the use of foam in 1944, generated by the simple process of 
shaking a sclerosant solution in a syringe with air. This produced foam with large 
bubbles and a high air-liquid ratio, which proved to be effective for smaller veins but 
not larger veins. However, it was not until 1963 that the technique of sclerotherapy 
was described and popularised by Fegan, whose name has become synonymous 
with the procedure.7 The interest in sclerotherapy plateaued in the 1980s, as the 
state of the art stagnated. Then in 1993, Juan Cabrera, began using a microfoam 
preparation  of  sodium tetradecyl  sulfate  and  polidocanol  for  sclerotherapy.  It 
represented a revolution in the treatment of venous diseases. 8
A 1998 survey on behalf  of  the Vascular Surgical  Society of  Great Britain and 
Ireland  showed  that  most  surgeons  reserved  sclerotherapy  for  either  primary 
varicose  veins  in  the  absence  of  superficial  venous  incompetence  (69.7%)  or 
residual varicose veins following surgery (77.1%).9 In 1997, Monfreux described 
foam produced with air in a glass syringe. The foam produced was quite durable 
but composed of relatively large bubbles. This method also required a learning 
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period to consistently produce high-quality foam. The large bubbles easily spread 
along the vessels and caused temporary patient dizziness or confusion at times. 
Other researchers soon developed other forms of foam with proven efficacy. Most 
recently, Frullini and Cavezzi10 and Tessari et al11 have described other variations 
in the production of foam. The Tessari method is now one of the most popular 
techniques, using 2 ordinary disposable syringes attached to a 3-way stopcock. Its 
popularity can be attributed to the simplicity and low cost of the method, and the 
production  of  high-quality  foam.  Several  large  series  have  been  published  to 
document the efficacy and safety of foam sclerotherapy.11,12 
A 10-year,  prospective,  controlled,  randomized  trial  involving over  800 patients 
conducted  by  vascular  surgeons  in  Europe  compared 6  treatment  options  for 
varicose  veins:  liquid  sclerotherapy, high-dose  liquid  sclerotherapy,  multiple 
ligations,  stab  avulsion, foam  sclerotherapy,  and  ligation  followed  by 
sclerotherapy.12 The report concluded that foam sclerotherapy appears to be more 
effective than standard-dose liquid sclerotherapy, and results can be comparable to 
surgery. Interestingly, this study also looked at lung scintigraphy in select patients 
who  received foam.  The  investigators  found  no  perfusion  defect  even  after 
injections of up to 10 mL of foam.12 Although foam sclerotherapy is effective for 
veins of  all  sizes, some researchers have noted a slightly higher rate of  minor 
adverse effects such as pigmentation, inflammation, and minimal necrosis when 
foam is used for small reticular veins and telangiectasias. 10
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A  recent  randomized  trail  found  that  ultrasound  guided  foam  sclerotherapy 
combined with sapheno-femoral ligation was less expensive, involved a shorter 
treatment time and resulted in more rapid recovery compared to sapheno-femoral 
ligation, saphenous stripping and phlebectomies. 13 
3.3 Chronic venous insufficiency
3.3.1 Epidemiology
Varicose veins are a common finding with  a point  prevalence of 20 to 25% in 
females and 10 to 15% in males over the age of 15 years. 14 It is difficult to find a 
satisfactory definition of varicose veins upon which consensus has been reached. 
Minor venous abnormalities such as thread veins are also seen in up to 50 to 55% 
of women and 40 to 50% of men. 
The symptoms attributable to varicose veins, and their correlation with the extent of 
venous  reflux,  are  not  clearly  defined.  Epidemiological  evidence  suggests  that 
even in the presence of 'main stem' varicose veins, most lower limb symptoms 
have  a  non-venous  cause2.  The  Edinburgh  Vein  Study  has  demonstrated 
superficial venous reflux in 9% of randomly selected men and 15% of women as 
well as deep venous reflux in 22% of men and 11% of women.15 
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3.3.2 Normal Venous Anatomy and Function
Fig 1.  Normal Venous Anatomy
The veins of the lower extremity are divided into the superficial and deep venous 
system connected by a series of perforator veins.16 
The superficial  venous system is located above the muscular fascial  layer.  It 
comprises  an  interconnecting  network  of  veins, which  serve  as  the  primary 
collecting system, and several truncal superficial veins, which function as a conduit 
18
to return blood to the deep venous system. The principal named superficial veins of 
the lower extremity are the short (or lesser) saphenous vein, which runs from the 
ankle typically to join the popliteal vein at the saphenopopliteal junction, and the 
great saphenous vein, which runs from the ankle to join the common femoral vein 
at the saphenofemoral junction. Other superficial veins, including the posterior arch, 
lateral accessory saphenous, and vein of Giacomini, also can develop pathology 
leading to CVI. 
The deep venous system is located below the muscular fascia and serves as 
collecting veins and the outflow from the extremity. The deep veins of the lower 
extremity consist of axial veins, which follow the course of the major arteries, and 
the intramuscular veins. Venous sinusoids within the leg muscles coalesce to form 
intramuscular  venous  plexi.  The  paired  calf  veins,  corresponding to  the  axial 
arteries, merge to form a single large popliteal vein. The popliteal vein, on passing 
through the adductor canal, is subsequently known as the femoral (often called the 
superficial femoral) vein. The femoral vein is joined by the profunda femoris (or 
deep femoral)  vein in the upper thigh to form the major outflow of the leg, the 
common femoral and eventually the external iliac vein. The superficial veins are 
connected to the deep venous system by a number of perforating veins in the thigh 
and leg that pass through anatomic fascial spaces. 
A series of bicuspid valves are located throughout the deep and superficial veins 
and ensures that blood moves in the cephalad direction, preventing the return of 
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blood toward the feet while in the upright posture. The first of these lower-extremity 
valves  is usually located in the common femoral  vein  or  less commonly in  the 
external iliac vein. The frequency of venous valves increases from the proximal to 
the distal leg to prevent an increase in pressure within the distal veins resulting 
from the  effects  of  gravity.  Perforating  veins  also  contain  one-way valves  that 
prevent reflux of blood from the deep veins into the superficial system. 
The valves function in concert with venous muscle pumps to allow the return of 
blood against gravity to the heart. Contraction of the muscle pumps primarily in the 
calf, but also in the foot and thigh, and forces blood out of the venous plexi and up 
the deep  venous  system  because  of  increased  pressure  within  the fascial 
compartments. The valve system prevents blood from being forced distally within 
the  deep  venous  system  or  through  the perforator  system  into  the  superficial 
system. Immediately after ambulation, the pressure within the veins of the lower 
extremity is normally low (15 to 30 mm Hg) because the venous system has been 
emptied by the muscle pump function (Figure 1). Relaxation of the muscle pump 
then allows blood to return to the deep venous system via arterial inflow through 
the superficial and the distal deep venous systems. With prolonged standing, the 
veins slowly fill and become distended, allowing the valves to open and eventually 
increase pressure that  is  directly  related  to  the height  of the column of  blood. 
Contraction of the muscle pump will  again empty the veins and reduce venous 
pressure. 
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3.3.3 Pathophysiology: The macrocirculation
Signs  and  symptoms of  chronic  venous  insufficiency  (CVI)  result  from venous 
obstruction, venous reflux, calf muscle pump dysfunction, or combinations of these 
factors.  In  most  cases,  reflux  is  the  principal  cause.  Venous  insufficiency  is 
described as primary or secondary. Primary valvular incompetence is the diagnosis 
when  no obvious etiologic  mechanism of  valvular  dysfunction  canbe identified. 
Such  cases  may  develop  from  a  loss  of  elasticity  of  the  vein  wall.17 Valvular 
incompetence is described as secondary when there is an obvious antecedent 
event, most frequently a deep venous thrombosis (DVT)
Ambulatory venous pressure (AVP) is the simplest and direct measure of venous 
hypertension. Patients with  AVP of below 40 mmHg have minimal incidence of 
venous ulceration. Venous recovery time (VRT) has also been used as indicator of 
valve dysfunction. 
Fig 2. Illustrative ambulatory venous pressure measurements. (A) Normal venous 
pressure.  The  resting  standing  venous  pressure  is  80  to  90  mm  Hg.  The 
pressure drops with calf exercise to 20 to 30 mm Hg, or a >50% decrease. The 
return in pressure is more gradual, with refill taking >20 s. (B) Abnormal venous 
pressure with deep venous reflux. The drop in pressure with exercise is blunted 
(<50% decrease).  The return in venous pressure to  the resting level  is  rapid 
because of a short refill time (<20 s).
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3.3.4 Microciculatory abnormalities
There are many theories regarding the pathogenesis of venous ulcer. The oldest 
theories are venous stasis (Holmans 18in 1917) and arteriovenous shunts (Pratt19in 
1949, and Brewer20in1950). Homans suggested that hypoxia secondary to blood 
stasis was responsible for ulceration. Subsequent studies did not show hypoxia in 
the limb with ulcer.21,22 The theory of arteriovenous shunts was strongly contested 
22
by findings of Lindemayr et al., who used radioactive microspheres and could not 
demonstrate  shunts  in  patients  with  ulcer.23 The  more  recent  theories  have 
associated  CVI  with  microcirculatory  abnormalities,  with  the  generation  of  an 
inflammatory  response.  In  1982,  Browse  and  Burnand  suggested  that  venous 
hypertension  in  the  calf  muscular  pump  system  is  transmitted  through  the 
perforating/communicating  system  to  the  superficial  veins  of  the  skin  and  the 
subcutaneous tissue of the calf.  24 This increase in pressure would distend the 
local  capillary  bed  and  widen  the  endothelial  pores,  allowing  large  molecules, 
mainly fibrinogen,  to escape into the interstitial  fluid.  Insoluble fibrin complexes 
form due to an inappropriate fibrinolytic activity in blood and interstitial fluid. Fibrin 
deposited  around  the  capillary  forms  a  barrier  to  oxygen  and  other  nutrients, 
promoting cell death and ulceration (Fig. 1). However, Falanga and Eaglstein, in 
1993, could not demonstrate that the fibrin cuffs were a real barrier to diffusion, 
observing that they were discontinuous around the capillaries and that the venous 
ulcers healed despite their presence on the ulcer border. 25 
In 1988, Coleridge Smith et al. proposed an alternative hypothesis to better explain 
venous ulcer pathogenesis.  26 According to these authors, increased pressure in 
the venous system, in the orthostatic position, leads to a pressure decrease of 
capillary perfusion, reducing the capillary flux sufficiently to cause leukocyte trap. 
The  trapped  leukocytes  release  toxic  metabolites  of  oxygen  and  proteolytic 
enzymes which then cause capillary damage, making capillaries more permeable 
to  large  molecules  and  promoting  additional  leukocyte  trap.  The  permeability 
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increase  could  result  in  extravasation  of  fibrinogen  and  other  plasma  proteins 
which would cause fibrin cuff formation. The trapped leukocytes would additionally 
damage  the  circulation  of  the  affected  capillaries,  resulting  in  ischemic  areas 
around the capillary  loop (Fig.  3).  This  theory has been criticized because the 
studies were performed with patients whose cutaneous alterations were secondary 
to chronic venous hypertension. Therefore it is difficult to determine whether the 
leukocyte trap was causing the local inflammatory process or was secondary to it. 
In 1991, Claudy et al . proposed that activation of leukocytes released free radicals 
and proteolytic enzymes, and increased elastase activity, causing epithelial injury 
and  increased  vessel  permeability,  resulting  in  deposition  of  pericapillary 
fibrin.27Furthermore, these leukocytes would release tumor necrosis factor alpha 
(TNF-α),  which  decreases  fibrinolytic  activity,  and  secondarily  induces  the 
formation of pericapillary fibrin cuffs. Both fibrin and toxic metabolites released by 
leukocytes can explain the difficulties encountered in ulcer healing. 
In 1993, Falanga et al  . proposed that capillary distension or injury of endothelial 
cells  due  to  venous  hypertension  leads  to  extravasation  of  fibrinogens,  α2-
macroglobulins  and  other  macromolecules,  from  veins  to  dermis.25These 
macromolecules can cause a functional inhibition of endogenous growth factors, 
for  instance  transforming  growth  factor  –β  (TGF-β),  making  them  unable  to 
maintain tissue integrity and healing recovery (Fig. 3). 
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Fig.3  Scheme  for  the  theory  of  Falanga  and  Eaglstein 
There  is  evidence  supporting  this  hypothesis.  For  example,  there  are  growth 
factors abundantly present in venous ulcer, and some fluid collected from venous 
ulcers causes in vitro inhibition of proliferation of some types of important healing 
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cells, including fibroblasts, endothelial cells and keratinocytes.  28,29 Therefore, the 
microenvironment of venous ulcer is negative for these growth factors and makes 
healing difficult. The notion that venous ulcers contain a functional trap for growth 
factors would provide an explanation for unsuccessful single growth factor therapy, 
but it is difficult to explain how these events would cause inflammation and tissue 
death. The role of  activated leukocytes  in venous ulcer development has been 
studied. Monocytes are likely the leukocytes involved in many clinical stages in the 
development of CVI.  30 Besides activated monocytes, aggregates of monocytes–
platelets have been recently implicated in CVI and venous ulcer etiopathogenesis. 
Peyton et al  . were the first to show an increased number of these aggregates in 
patients with venous ulcer.31In 1999, Powell  et al  . showed an association of all 
classes of CVI with the increase of these circulating aggregate levels.32  They also 
suggested that the circulating aggregate of monocytes– platelets would be able to 
injure the venous endothelium and valves, leading to the development of valvular 
dysfunction.  The activated leukocytes  release the substances mentioned above 
and the activated platelets release interleukin-1 (IL-1) and TNF-α, and both would 
act  in  endothelial  cells  to  increase  leukocyte  adhesion  (Fig.  4).  However,  the 
stimuli that activate monocytes and platelets are still unknown, as are the roles of 
these circulating aggregates. Activated monocytes as a cause of CVI are still the 
subject of investigation. 
            Fig. 4 Scheme for the theory of Powell et al.
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In vivo microscopy studies have revealed areas of  capillary microthrombosis in 
lipodermatosclerotic skin33 and reductions in capillary numbers in areas of prior 
ulceration (atrophie blanche).34 This suggests that cutaneous nutrient circulation 
may contribute to venous ulceration and recurrence. Despite the many studies that 
have been carried out and the various hypotheses that have been proposed, the 
real  mechanism  of  CVI  development  and  venous  ulcer  is  still  unknown.  It  is 
possible  that  each  mechanism  described  above  is  important  in  some  cases. 
Therefore,  the  etiopathogenesis  of  these  diseases  is  still  the  subject  of  many 
current studies.
3.3.5 Risk factors 
Heredity plays a significant role in the development of varicose veins. Moderate 
venous  disease  is  independently  related  to  age,  previous  hernia  surgery,  and 
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normotension  in  both  sexes.  In  men,  current  walking,  the  absence  of 
cardiovascular disease, and not moving after sitting are also predictive. Additional 
predictors in women are weight, number of births, oophorectomy, flat feet, and not 
sitting.  For  severe  disease,  age,  family  history  of  venous  disease,  waist 
circumference, and flat feet are predictive in both sexes. In men, occupation as a 
labourer, cigarette smoking, and normotension are also independently associated 
with severe venous disease. Additional significant and independent predictors in 
women  are  hours  standing,  history  of  leg  injury,  number  of  births,  and 
cardiovascular disease, but African American ethnicity is protective.35
3.4 The C-E-A-P classification
This is a recent scoring system that stratifies venous disease based on  clinical 
presentation,  etiology,  anatomy, and  pathophysiology. This classification scheme 
is useful in helping the physician coherently and thoughtfully assess a limb afflicted 
with venous insufficiency and then arrive at an appropriate treatment plan.
Classification of Chronic Lower Extremity Venous Disease
C Clinical signs (grade0–6, supplemented by “A” for asymptomatic and “S” for symptomatic presentation
E Etiologic classification (congential, primary, secondary)
A Anatomic  distribution  (superficial,  deep,  or  perforator,  alone  or  in combination)
P Pathophysiologic dysfunction (reflux or obstruction, alone or in combination)
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CLINICAL CLASSIFICATION (C0–6) 
Any limb with possible chronic venous disease is first placed into one of seven 
clinical classes (C0–6) according to the objective signs of disease.
Clinical Classification of Chronic Lower Extremity Venous Disease 
Class 0 No visible or palpable signs of venous disease
Class 1 Telangiectasia, reticular veins, malleolar flare
Class 2 Varicose veins
Class 3 Edema without skin changes
Class 4 Skin changes ascribed to venous disease (e.g., pigmentation, venous eczema, lipodermatosclerosis)
Class 5 Skin changes as defined above with healed ulceration
Class 6 Skin changes as defined above with active ulceration
Limbs in higher categories have more severe signs of chronic venous disease 
and may have some or all of the findings defining a less severe clinical category. 
Each limb is further characterized as asymptomatic (A), for example, C0–6,A, or 
symptomatic (S),  for  example, C0–6,S.  Symptoms that may be associated with 
telangiectatic, reticular, or varicose veins include lower extremity aching, pain, 
and skin  irritation.  Therapy may alter  the clinical  category of  chronic  venous 
disease.  Limbs should therefore be reclassified after  any form of  medical  or 
surgical treatment.
ETIOLOGIC CLASSIFICATION (EC, EP, or ES) 
Venous dysfunction may be congenital, primary, or secondary. These categories 
are mutually exclusive. Congenital venous disorders are present at birth but may 
not  be  recognized  until  later.  The  method  of  diagnosis  of  congenital 
abnormalities  must  be  described.  Primary  venous  dysfunction  is  defined  as 
venous dysfunction of unknown cause but not of congenital origin. Secondary 
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venous dysfunction denotes an acquired condition resulting in chronic venous 
disease, for example, deep venous thrombosis.
Etiologic Classification of Chronic Lower Extremity Venous Disease 
Congenital 
(EC) Cause of the chronic venous disease present since birth
Primary (EP) Chronic venous disease of undetermined cause
Secondary 
(ES)
Chronic venous disease with an associated known cause (post-
thrombotic, post-traumatic, other)
ANATOMIC CLASSIFICATION (AS, AD, or AP) 
The anatomic site(s) of the venous disease should be described as superficial 
(AS), deep (AD), or perforating (AP) vein(s). One, two, or three systems may be 
involved  in  any  combination.  For  reports  requiring  greater  detail,  the 
involvement of the superficial, deep, and perforating veins may be localized by 
use of the anatomic segments.
Segmental Localization of Chronic Lower Extremity Venous Disease 
Segment No. Vein(s)
SuperficialVeins (AS1–5)
1 Telangiectasia/reticular veins
Greater (long) saphenous vein
2 Above knee
3 Below knee
4 Lesser (short) saphenous vein
5 Nonsaphenous
Deep Veins (AD6–16)
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Segment No. Vein(s)
6 Inferior vena cava
Iliac
7 Common
8 Internal
9 External
10 Pelvic: gonadal, broad ligament
Femoral
11 Common
12 Deep
13 Superficial
14 Popliteal
15 Tibial  (anterior,  posterior,  or peroneal)
16 Muscular  (gastrointestinal,  soleal, other)
Perforating Veins (AP17,18)
17 Thigh
18 Calf
PATHOPHYSIOLOGIC CLASSIFICATION (PR,O) 
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Clinical  signs or symptoms of chronic venous disease result  from reflux (Pr), 
obstruction (Po), or both (Pr,o).
Pathophysiologic  Classification  of  Chronic  Lower  Extremity  Venous 
Disease 
Reflux (PR)
Obstruction (PO)
Reflux and obstruction (PR,O)
3.3.7 Clinical features
The patient with symptomatic varicose veins relates, most often, symptoms of 
aching, heaviness, discomfort,  and sometimes outright pain in the calf  of  the 
affected limb.  Many causes of leg pain are possible,  and most  may coexist. 
Therefore,  defining  the precise symptoms of  venostasis  is  necessary.  These 
symptoms may be of gradual onset or may be initiated by a lancinating pain, and 
they may precede the clinical appearance of the varicosity. Discomfort usually 
occurs during warm temperatures and after prolonged standing. Varicose vein 
symptoms  are  often  disproportionate  to  the  degree  of  pathologic  change. 
Patients with  small,  early  varices  may complain  more  than those with  large, 
chronic varicosities. The initial symptoms may vary from a pulsating pressure or 
burning sensation to a feeling of heaviness. The pain is characteristically dull, 
does not occur during recumbency or early in the morning, and is exacerbated in 
the afternoon, especially after long standing. This is particularly worse at the end 
of the day, most likely due to prolonged sitting or standing that results in venous 
distention and associated pain. The discomforts of aching, heaviness, fatigue, or 
burning pain are relieved by recumbency, leg elevation, or elastic support.
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In the case of women, the symptoms are often most troubling and exacerbated 
during the menstrual period, particularly during the first day or two. It is not unusual 
for a patient to have significant reflux at the saphenofemoral junction and yet not 
have impressive varicose veins on physical examination. Additionally, the patient 
may have combined superficial and deep venous insufficiency, and thus a clear 
diagnosis, with the aid of the CEAP system, is useful in determining treatment.
Primary varicose veins consist  of  elongated,  tortuous, superficial  veins that  are 
protuberant and contain incompetent valves. These produce the symptoms of mild 
swelling,  heaviness,  and  easy  fatigability.  Primary  varicose  veins  merge 
imperceptibly into more severe CVI. Swelling is moderate to severe, an increased 
sensation of heaviness occurs with larger varicosities, and early skin changes of 
mild  pigmentation  and  subcutaneous  induration  appear.  When  CVI  becomes 
severe,  marked swelling and calf  pain  occur  after  standing,  sitting,  or  walking. 
Multiple dilated veins are seen associated with various clusters and heavy medial 
and lateral supramalleolar pigmentation.
.Cutaneous itching is  also  a sign of  venostasis  and is  often  the hallmark  of 
inadequate external support. It is a manifestation of local congestion and may 
precede the onset  of  dermatitis.  This,  and nearly  all  the symptoms of  stasis 
disease, can be explained by the irritation of  superficial  nerve fibers by local 
pressure or accumulation of metabolic end products with a consequent pH shift. 
External  hemorrhage may occur  as  superficial  veins  press  on  overlying  skin 
within this protective envelope.
3.3.8 Complications
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Chronic  venous  insufficiency  can  lead  to  hyperpigmentation, 
lipodermatosclerosis and superficial thrombophlebitis. There is an increased risk 
of cellulitis, leg ulceration, and delayed wound healing. Long-standing CVI also 
may lead to the development of lymphedema. Long standing ulcers can give rise 
to Marjolin’s ulcer (squamous cell carcinoma).
3.3.9 Evaluation
The most important of all noninvasive tests available to study the venous system 
are the physical examination and a careful history that elucidates the symptoms 
mentioned earlier. Clinical examination of the patient  determines the nature of the 
venostasis  disease  and  ascertains  the  presence  of  intercutaneous  venous 
blemishes  and  subcutaneous  protuberant  varicosities,  the  location  of  principal 
points of control or perforating veins that feed clusters of varicosities, the presence 
and location of ankle pigmentation and its extent, and the presence and severity of 
subcutaneous induration. After these facts have been obtained, the physician may 
turn  to  noninvasive  techniques  to  corroborate  the  clinical  impression.  Visual 
examination  can  be  supplemented  by  noting  a  downward-going  impulse  on 
coughing.  Tapping  the  venous  column  of  blood  also  demonstrates  pressure 
transmission through the static column to incompetent distal veins.
The Perthes test for deep venous occlusion and the Brodie-Trendelenburg test of 
axial reflux have been replaced by in-office use of the continuous-wave, handheld 
Doppler instrument supplemented by duplex evaluation.36 The handheld Doppler 
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instrument  can  confirm  an  impression  of  saphenous  reflux,  and  this,  in  turn, 
dictates the operative procedure to be performed in a given patient. It is used in 
specific  locations to determine incompetent  valves.  With distal  augmentation of 
flow and release, with normal deep breathing, and with performance of a Valsalva 
maneuver,  accurate  identification  of  valve  reflux  is  ascertained.  Formerly,  the 
Doppler examination was supplemented by other objective studies. These included 
the  photoplethysmograph,  the  mercury  stain-gauge  plethysmograph,  and  the 
photorheograph. These are no longer in use. Another instrument reintroduced to 
assess physiologic function of the muscle pump and the venous valves is the air-
displacement plethysmograph.37 This instrument was discarded after its use in the 
1960s because of its cumbersome nature. Computer technology has allowed its 
reintroduction as championed by Christopoulos and coworkers.37 It consists of an 
air chamber that surrounds the leg from knee to ankle. During calibration, leg veins 
are emptied by leg elevation, and the patient is then asked to stand so that leg 
venous volume can be quantitated and the time for filling recorded. The filling rate 
is then expressed in milliliters per second, thus giving readings similar to those 
obtained with the mercury strain-gauge technique.
Duplex technology more precisely defines which veins are refluxing by imaging the 
superficial  and  deep  veins.  Valve  closure  requires  a  reversal  of  flow  with  a 
pressure  gradient  that  is  higher  proximally  than  distally.38 Thus,  the  duplex 
examination should be done with the patient standing or in the markedly trunk-
elevated position.39,40
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Imaging is obtained with a 10- or 7.5-MHz probe, and the pulsed Doppler consists 
of a 3.0-MHZ probe. The patient stands with the probe placed longitudinally on the 
groin.  After  imaging,  sample  volumes  can  be  obtained  from  the  femoral  or 
saphenous vein. This flow can be observed during quiet respiration or by distal 
augmentation.  Sudden  release  of  augmentation  allows  assessment  of  valvular 
competence. The short saphenous vein and popliteal veins are similarly examined. 
Imaging improves the accuracy of the Doppler examination. Widespread use of 
duplex scanning has allowed a comparison of findings between standard clinical 
examinations with duplex Doppler studies.41 In a study in which each patient was 
examined  by  three  surgeons  using  different  techniques  (one  using  clinical 
examination, a second using the handheld Doppler instrument, and a third using a 
color duplex scanner), it  was found that clinical examination failed in assessing 
main axial  reflux at  the saphenofemoral junction and saphenopopliteal  junction. 
Whenever  a  Doppler  instrument  was  added to  the  examination,  the  evaluation 
became  more  accurate.  Based  on  preoperative  assessments  using  clinical 
examination alone, inappropriate surgery would have been performed in 20% of 
the limbs. Clinical examination plus Doppler study would have produced a 13% 
incidence of inappropriate surgery.
Phlebography 
In general,  phlebography is unnecessary in diagnosis and treatment of  primary 
venostasis disease and varicose veins. In the complex problems of severe CVI, 
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phlebography  has  specific  utility.  Ascending  phlebography  defines  obstruction. 
Descending phlebography identifies specific valvular incompetence suspected on 
B-mode scanning and clinical examination.
3.3.10 Treatment options
Nonoperative  management includes avoidance of prolonged standing or  sitting, 
use  of  elastocrepe  bandage  or  stockings,  elevation  of  lower  limbs  and 
compression therapy. Recently some drugs e.g., microflavanoids have also been 
used.
The standard surgical treatment is Trendelenburg’s operation, stripping of great 
saphenous vein and multiple stab avulsions of perforators. Subfascial endoscopic 
perforator  ligation,  endovenous  laser  therapy,  radiofrequency  ablation, 
transilluminated power phlebectomy and foam sclerotherapy are other modalities 
of treatment.
3.4 Venous ulcer42
Venous ulcers constitute approximately 80% of all leg ulcers. Venous leg ulcers 
have been estimated to afflict 0.2% to 1% of the total population and 1% to 3% of 
the elderly.43
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3.4.1 Diagnosis of lower extremity ulcers
Gross arterial disease should be ruled out by establishing that pedal pulses are 
present on physical examination and/or that the ankle : brachial index (ABI) is > 
0.8.  (Any  ABI  less  than  1.0  suggests  a  degree  of  vascular  disease  and 
compression therapy is usually considered to be contraindicated with  an ABI < 
0.7.) In elderly patients, patients with diabetes mellitus, or patients with an ABI > 
1.2, a toe: brachial index of > 0.6 or a trans-cutaneous oxygen partial pressure of > 
30mmHg in the region of the ulcer may help to suggest an adequate arterial flow.
Color  duplex  ultrasound  scanning  performed  with  proximal  compression  or  a 
Valsalva maneuver is useful in providing anatomic and physiologic data helping to 
confirm a venous etiology for the leg ulcer.  Patients presenting with an apparent 
venous ulcer and who are suspected of having sickle cell disease should have a 
sickle cell  prep and a hemoglobin electrophoresis.  Apparent venous ulcers that 
have been open continuously without signs of healing for 3 months or that do not 
demonstrate  any  response  to  treatment  after  6  weeks  should  be  biopsied  for 
histological diagnosis.44  This is to rule out malignancy, vasculitis, collagen-vascular 
diseases, and dermal manifestations of systemic diseases.
Apparent venous ulcers, as well as all wounds, that are excessively painful and 
that  progressively  increase  in  size  after  debridement  and/or  despite  treatment 
should be considered for other diagnoses such as pyoderma gangrenosum, IgA 
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monoclonal  gammopathies,  Wegener’s  granulomatosis,  cutaneous  chronic 
granulomatous  disease,  and  mycobacterial  or  fungal  etiologies.  This  suspicion 
should be especially high if the ulcer is darker in color, has blue/purple borders, or 
if the patient has a systemic disease such as Crohn’s disease, ulcerative colitis, 
rheumatoid arthritis, collagen vascular diseases, leukemia, or immunosuppression.
3.4.2 Lower extremity compression 
The use of a Class 3 (most supportive) high-compression system (three layer, four 
layer, short stretch, paste-containing bandages, e.g., Unna’s boot, Duke boot) is 
indicated in the treatment of venous ulcers. Although these modalities are similar in 
effectiveness,  they  can  differ  significantly  in  comfort  and  cost.  The  degree  of 
compression must be modified when mixed venous/arterial disease is confirmed 
during the diagnostic work-up. Intermittent pneumatic pressure (IPC) can be used 
with or without compression dressings and can provide another option in patients 
who cannot or will not use an adequate compression dressing system.
3.4.3 Infection control 
Infection results when the bacteria: host defense equilibrium is upset in favor of the 
bacteria. Infection plays various roles in the etiology, healing, operative repair, and 
complications of venous ulcers.  Remove all necrotic or devitalized tissue by sharp, 
enzymatic,  mechanical,  biological,  or  autolytic  debridement.  If  infection  is 
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suspected  in  a  debrided  ulcer,  or  if  epithelialization  from  the  margin  is  not 
progressing within 2 weeks of debridement and initiation of compression therapy, 
determine the type and level of infection in the debrided ulcer by tissue biopsy or 
by a validated quantitative swab technique.45 For ulcers with >/=1x106 CFU/g of 
tissue  or  any  tissue  level  of  beta  hemolytic  streptococci  following  adequate 
debridement, decrease the bacterial level with topical antimicrobial therapy. Once 
in  bacterial  balance,  discontinue  the  use  of  the  topical  antimicrobial  agent  to 
minimize  any  possible  cytotoxic  effects  due  to  the  antimicrobial  agent  or 
emergence of bacterial resistance to the agent. Cellulitis surrounding the venous 
ulcer should be treated with systemic gram-positive bactericidal antibiotics. 
3.4.4 Wound bed preparation 
Wound bed preparation is defined as the management of the wound to accelerate 
endogenous  healing  or  to  facilitate  the  effectiveness  of  other  therapeutic 
measures.
The  aim  of  wound  bed  preparation  is  to  convert  the  molecular  and  cellular 
environment of a chronic wound to that of an acute healing wound.
Examination of the patient as a whole is important to evaluate and correct causes 
of  tissue  damage.  This  includes  factors  such  as:  systemic  diseases  and 
medications,  nutrition, and tissue perfusion and oxygenation. 
Initial  debridement is required to remove the obvious necrotic tissue, excessive 
bacterial burden, and cellular burden of dead and senescent cells. Maintenance 
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debridement is needed to maintain the appearance and readiness of the wound 
bed  for  healing.  The  health  care  provider  can  choose  from  a  number  of 
debridement  methods  including  sharp,  enzymatic,  mechanical,  biological,  or 
autolytic.  More  than  one  debridement  method  may  be  appropriate.   Wounds 
should  be  cleansed  initially  and  at  each  dressing  change  using  a  neutral, 
nonirritating, nontoxic solution. Routine wound cleansing should be accomplished 
with a minimum of chemical and/or mechanical trauma. 
3.4.5 Dressings  
There  is  a  plethora  of  choices  for  topical  treatment  of  venous  ulcers.  Many 
dressings  now  combine  wound  bed  preparation,  i.e.,  debridement  and/or 
antimicrobial activity, with moisture control. Guidelines are necessary to help the 
clinician  make decisions  regarding  the  value  and  best  use  of  these advanced 
wound  care  products.  Most  dressings  will  be  used  in  combination  with 
compression systems.
 Use  a  dressing  that  will  maintain  a  moist  wound-healing  environment. 
Continuously moist saline gauze dressings are as effective as other types of moist 
wound healing in terms of healing rate, although they may have other drawbacks 
such  as  maceration  of  the  peri-ulcer  skin,  practicality  of  use,  and  cost 
effectiveness. The use of compression systems for venous ulcers alleviates the 
need  for  adhesive  to  keep  the  primary  dressing  in  place.  However,  additional 
tissue damage may result if the dressing causes increased pressure on the wound 
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or damages adjacent tissue. Venous ulcer patients are particularly susceptible to 
contact dermatitis related to topical therapies. Because of their low unit cost, moist 
saline gauze dressings are often viewed as the least expensive and, therefore, 
most  cost-effective  dressing.  Emerging  therapies  through  recombinant 
technologies  and cell-based devices  may offer  benefit  and increase healing  in 
selected patients or difficult wounds.
3.4.6 Surgery in venous ulcer
The  mainstay  of  moist  wound  dressings  and  a  compression  system  are  not 
successful in healing all venous ulcers. Also, they do not fully address the etiology 
of  increased  ambulatory  venous  pressure.  Over  the  years,  multiple  surgical 
procedures have been attempted to treat venous ulcers with varying degrees of 
success. True randomized clinical trials comparing operative techniques are rare in 
the literature, but data are available supporting surgery in selected patients.
Skin grafting of a venous ulcer, without attention to the underlying venous disease, 
is  not  a  long-term  solution  and  is  prone  to  recurrent  leg.   Trendelenburg’s 
operation  along  with  stripping  of  great  saphenous  vein  and  stab  avulsions  of 
perforators is the standard procedure. Subfascial  endoscopic perforator surgery 
(SEPS) can also be combined with Trendelenburg’s operation. The procedure is 
not effective if the patient has severe deep venous disease with either deep reflux 
or obstruction. 
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Less extensive surgery on the venous system such as superficial venous ablation, 
endovenous  laser  ablation,  or  valvuloplasty,  especially  when  combined  with 
compression therapy, can be useful in decreasing the recurrence of venous ulcers. 
Free flap transfer with microvascular anastomoses can benefit recalcitrant venous 
ulcers  with  severe  lipodermatosclerosis  by  allowing  wide  excision  of  diseased 
tissue and providing uninjured venous valves in the transferred tissue.46
3.4.7 Use of adjuvant agents (topical, device and systemic)  
Cytokine growth factors have yet to be shown to demonstrate sufficient statistically 
significant  results  of  effectiveness to  recommend any of  them for  treatment  of 
venous ulcers, although isolated reports suggest their potential usefulness. There 
is evidence that  a bilayered artificial  skin (biologically active dressing),  used in 
conjunction  with  compression  bandaging,  increases  the  chance  of  healing  a 
venous  ulcer  compared  with  compression  and  a  simple  dressing.  Cultured 
epithelial autografts or allografts have not been demonstrated to improve stable 
healing of venous ulcers. Electrical stimulation may be useful in reducing the size 
of venous leg ulcers.47  Negative pressure wound therapy may be useful prior to a 
skin  graft/flap by helping promote the development of  granulation tissue in  the 
wound base, or postoperatively by preventing shearing and removing exudates. 
However,  its  reported  experience  in  venous  ulcers  is  limited.48  Laser  therapy, 
phototherapy, and ultrasound therapy have not been shown statistically to improve 
venous ulcer healing. Sclerotherapy may be useful as an adjunct to compression 
therapy in the treatment of venous ulcers. 49
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Pentoxifylline used in conjunction with compression therapy improves healing of 
venous  ulcers  by  improving  microcirculation.  The  role  of  eicosanoids 
(prostaglandins)  or  prostaglandin antagonists  in  the treatment  of  venous ulcers 
lacks sufficient data to allow a recommendation. Oral treatment with micronized 
purified  flavonoid  fraction  (MPFF)  may  be  a  useful  adjunct  to  conventional 
compression  therapy  in  the  treatment  of  leg  ulcers.50  These  agents  inhibit  the 
synthesis  of  free  oxygen  radicals,  decrease  microvascular  leakage,  and  inhibit 
leukocyte  trapping  and  activation.  Fibrinolytic  enhancement  with  an  anabolic 
steroid such as stanozolol in conjunction with compression therapy may be useful 
in treating lipodermatosclerosis associated with venous ulcers. However, one must 
be aware of side effects. Oral zinc supplementation is not useful in the treatment of 
venous leg ulcers.
3.5 Foam Sclerotherapy
3.5.1 Sclerotherapy 
Sclerotherapy  is the targeted elimination of intracutaneous, subcutaneous, and/or 
transfascial  varicose  veins  (perforating  veins)  as  well  as  the  sclerosation  of 
subfascial varicose vessels in the case of venous malformation by the injection of a 
sclerosant. The various sclerosants provoke a marked damage of the endothelium 
of the vessels and possibly of the entire vascular wall. Subsequently, a secondary, 
wallattached local thrombus is generated, and in the longterm, the veins will  be 
transformed into a fibrous cord, that is, sclerosis51. The purpose of sclerotherapy is 
not just a thrombosis of the vessel, which, per se, is subject to recanalization, but 
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the  definite  transformation  into  a  fibrous  cord.  This  cannot  recanalize  and 
corresponds to the surgical  removal  of  a varicose vein as far  as the functional 
result is concerned.
3.5.2 Sclerosing foam 
This is a nonequilibrium dispersion of gas bubbles in a sclerosing solution, where 
the  sclerosing  solution  contains  surface-active  molecules,  where  the  gas  is 
physiologically tolerated at therapeutic doses, and where the gas fraction is equal 
to or greater than 0.52. Sclerosing foam is characterized by (at least) the following 
variables: type and concentration of the tensioactive sclerosing agent, type of gas, 
ratio of liquid to gas, the method of preparation, the time between processing and 
use, and bubble sizes. The behavior of sclerosing foam is quite different compared 
to the action and the properties of liquid sclerosing solutions52.
3.5.3 Foam vs liquid sclerotherapy
Foam sclerotherapy holds several advantages over traditional liquid sclerotherapy. 
Once a liquid is injected, it mixes with the blood in the vein, and the concentration 
of the sclerosant is diluted. Foam, on the other hand, displaces the blood, allowing 
direct  contact  of  the  sclerosant  with  the  endothelium.  The  efficacy of  a  given 
concentration of sclerosant is effectively increased when used as foam instead of 
liquid. Accordingly, we can use a lower concentration of a given sclerosant to treat 
veins. This increases the safety of sclerotherapy.  Greater safety is also achieved 
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with foam for other reasons. A given volume of liquid can be used to produce 4 or 5 
times its volume in foam, depending on the foaming method. This allows  the use of 
lower  total  dose  of  the  sclerosant  to  achieve  the desired  effect.  Moreover, 
extravasated  foam  is  much  better  tolerated than  extravasated  liquid.  The  air 
contained in  the  foam  is  echogenic.  This  dramatically  increases  visibility and 
accuracy when performing duplex-guided sclerotherapy.
Besides  being  composed  of  different  specific  ingredients, foams  can  differ  in 
compactness, durability, and density. Compactness is related to the size of the air 
bubbles.  Macrofoam  contains bubbles  larger  than  500  µm;  minifoam  contains 
bubbles between 250 and 500 µm; and microfoam is composed of bubbles smaller 
than 250 µm. Since smaller bubbles ensure better contact with the endothelium for 
most  therapeutic  purposes, most  experts  would  prefer  microfoam,  and  most 
methods of foam production would strive to achieve this standard. 
3.5.4 Pathophysiology
After sclerotherapy the pathologic damage is immediate. After only 2 minutes of 
foam  drug  exposure,  the  endothelial  and  part  of  tunica  media  are  seriously 
damaged and after a few minutes the detachment of the endothelial epithelium. 
The sclerosis developed after only 30 minutes with
the presence of a microthrombus. In only 30 minutes with the foam sclerotherapy, 
the same result is obtained that which is obtained in almost 2 to 3 hours by the 
liquid sclerotherapy53. In our report, there is no histologic difference among the six 
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patients.  The  endothelial  damage  was  synchronous:  necrosis,  endothelial 
detachment, and early sclerosis developed from the vein wall54. 
3.5.5 Safety of foam
The  stress  that  foam places  on  the  human  respiratory  system is  still  unclear, 
although complications rates are exceedingly low. Frullini and Cavezzi proposed a 
limit  of  3  mL  of  foam per  each  session  of  sclerotherapy,  although  no  major 
complications such  as  pulmonary  embolism,  deep  vein  thrombosis,  ischemic 
lesions, or anaphylactic reaction were recorded. Others suggest less than 10 mL, 
while some routinely use up to 40 mL without serious sequelae. However, when 
larger doses are used, there are incidents of dry cough, chest discomfort, transient 
ischemic attacks, and scotomas. 
Of  note,  Cabrera  et  al  used  up  to  80  mL  without  respiratory or  neurologic 
complications. The decision to use such large volumes may rely on the use of 
carbon dioxide instead of room air. Carbon dioxide has much higher solubility than 
nitrogen, the primary component of room air. However, no publication to date has 
compared the effect of different gases. 
Although sterile gas may be preferred from a medical-legal standpoint, in everyday 
practice the use of filtered air seems unnecessary. Frullini  points out that while 
operating-room  air  is  not  sterile, surgeons  commonly  expose  the  interior  of  a 
patient for hours during major operations.
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In a prospective study of large-volume foam sclerotherapy for venous insufficiency, 
no deep vein thrombosis was detected in patients experiencing leg pain or swelling 
after the procedure. But since deep vein thrombosis can be clinically silent, some 
may have been missed. 
Studies have revealed that a precapillary arteriovenous shunt might allow a direct 
flow of sclerosant from the venous to the arterial circulation. Therefore, even with 
expert  technique  using  a  conservative  sclerosant  dose  and concentration, 
cutaneous ulcerations may occur. 
Mason et al examined the coagulation status of patients with vascular anomalies 
who  had  undergone  sclerotherapy  or  embolization by  measuring  fibrinogen, 
platelet,  D-dimer  levels,  and  prothrombin time for  29  patients  before  and  after 
treatment.  The  researchers concluded  that  patients  who  received  dehydrated 
alcohol  or  sodium tetradecyl  sulfate  sclerotherapy might experience coagulation 
abnormalities  that  put  them  at  increased  risk  for  bleeding, thrombosis,  or 
hematoma. Similar studies have not been done for foam sclerotherapy of venous 
malformations. 
3.5.6 Indications
The objectives of sclerotherapy are:
• Treatment of varicosis and prevention of possible complications
• Reduction or elimination of existing symptoms
• Improvement of pathologically altered hemodynamics and 
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• Achievement  of  a  good  result  that  satisfies  aesthetic  and  functional 
criteria.55
In principle all vein calibers are suitable for foam sclerotherapy. Foam gives a 
better outcome in larger vein calibers (C2 varicose veins) and recurrent varicose 
veins (compared to conventional sclerotherapy). Some published data show good 
results in venous malformations. The larger the diameter of the vein,  the more 
viscous the foam should be to obtain better results. The smaller the diameter of the 
vein the more liquid the foam should be for easier injection and to reduce possible 
tissue damage. With viscous foams a lower caliber threshold exists. Below that, 
vein-size viscous foams could cause more tissue damage.
Possible New Indications for Foam Sclerotherapy56,57
• Interventional angioradiologic procedures
• Pelvic congestion syndrome
• Varicocele
• Hydrocele
• Angiodysplasia
• Metastatic lesions
• Vascular malignant tumors
• Baker’s cyst
• Hemorrhoids58
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3.5.7 Contraindications
Absolute contraindications are:
• Known allergy to the sclerosant
• Severe systemic disease 
• Acute superficial or deep vein thrombosis 
• Local infection in the area of sclerotherapy or severe generalized infection 
• Immobility 
• Confinement to bed 
• Advanced peripheral arterial occlusive disease 
• Hyperthyroidism (in the case of sclerosants containing iodine) and
• Pregnancy in the first trimester and after the 36th week of gestation.
Relative contraindications are:
• Leg edema
• Late complications in diabetes (e.g., polyneuropathy)
• Mild peripheral arterial occlusive disease 
• Poor general health
• Bronchial asthma
• Marked allergic diathesis
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• Known hypercoagulability and
• Thrombophilia with history of deep vein thrombosis
• Patent foramen ovale
3.5.8 Complications and Risks
If  performed properly,  sclerotherapy is an efficient treatment method with a low 
incidence of complications. Nevertheless, a series of adverse events may occur in 
the context of the therapy. 
Categorization of Sclerotherapy Complications59
Frequent, transient
        Telangiectatic matting (10–30%)
 Postsclerotherapy pigmentation (10–30%)
 Pain with injection 
 Urtication post-injection (worse with polidocanol) 60 
Rare, self-limited
 Cutaneous necrosis 61
 Superficial thrombophlebitis
 Nerve damage (saphenous, sural) 62
 Transient visual disturbances, especially in migraine patients,
 Hematuria  
Rare, major
 Anaphylaxis
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 Deep vein thrombosis, pulmonary embolism
Early reaction type allergy up to anaphylactic shock as well as an inadvertent 
intraarterial  injection  are  very  rare  complications  constituting  an  emergency 
situation. Skin necroses are described after paravascular injection of sclerosants in 
higher concentrations as well as, but rarely, after properly performed intravascular 
injection with various sclerosants, for example, 0.5% polidocanol in the treatment 
of spider veins.
In  the  second  case,  a  mechanism  involving  transition  of  the  sclerosant  via 
arteriovenous anastomoses into arterial vessels has been discussed. In individual 
cases, this was described as embolia cutis medicamentosa.
Hyperpigmentations  are  described  with  a  frequency  of  0.3% to  10%.  In 
general,  they  regress  slowly.  Matting,  fine  telangiectasias  in  the  area  of  a 
sclerosed vein, is an unpredictable individual reaction of the patient and can also 
occur after surgical removal of a varicose vein.
Nerve  damage  has  been  described  experimentally  after  paravascular 
injection. Further transitory appearances after sclerotherapy are intravascular clots, 
phlebitis,  and  hematomas.  Additionally,  complications  may  arise  from  the 
compressive bandage such as, for example, formation of blisters.
Intravascular clots can be squeezed out after stab incision to reduce the 
development of hyperpigmentation. Sclerotherapy is an intervention that requires 
patient information.
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With large (20 mL) or very large amounts (33 mL and more)  63,  64 deep 
venous thromboses have been reported. For liquid foams prepared from diluted 
liquid  sclerosing  solutions,  there  is  probably  a  higher  incidence  of  visual 
disturbance and migraine in patients predisposed to these conditions.65
3.5.9 Diagnostics before Sclerotherapy
 
Diagnostic  evaluation  includes  study  of  the  medical  history,  clinical 
examination, and Doppler ultrasonography.  Additionally,  functional  examinations 
(e.g.,  photoplethysmography,  phlebodynamometry,  venous  occlusion 
plethysmography) and imaging (e.g., duplex ultrasonography, phlebography) can 
be taken into consideration. Functional examinations make it possible to assess 
the improvement of venous function, which is to be expected for the elimination of 
varicosis.  Diagnostic  imaging  is  especially  suited  for  the  identification  of 
incompetent communications with the deep venous system, diagnostic clarification 
of  postthrombotic  alterations,  and  the  assessment  of  a  combined  surgical 
treatment that may have to be performed.66
3.5.10 Methods for the Preparation of Extemporary Foam
i) The Monfreux method
Sclerosing  foam is  generated  using  a  glass  syringe  that  contains  liquid 
sclerosing solution. The outlet of the syringe is sealed by a rubber or plastic cap. 
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Pulling back the piston generates a subatmospheric pressure, drawing air into the 
syringe through the gap between the syringe body and the piston. A rather fluid 
foam with fairly large bubbles is generated. 67
Figure 4. Methods for the preparation of extemporary foam. Left,
Monfreux technique; middle, Tessari technique; right, double-syringe technique.
ii) The Tessari technique 
Sclerosing  foam is  generated  with  two  disposable  plastic  syringes.  One 
syringe  contains  the  liquid  sclerosing  solution,  and the  other  contains  air.  The 
outlets of the syringes are connected with a three-way tap or a two-way-connector. 
Pumping the contents of both syringes backward and forward (approximately 20 
times for the original Tessari technique (also known as Tourbillion technique) or 5 
times with additional pressure and 7 times without additional pressure for the DSS 
technique, a variation of the basic technique by Tessari) causes a turbulent flow 
that generates foam. The liquid-to-air ratio varies from 1:4 (one plus three) to 1:5 
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(one plus four) for the original Tessari technique. Tessari’s technique gives small-
bubbled foam, which is rather fluid if low concentrations of sclerosants are used or 
viscous if high concentrations of sclerosants are used. Foam properties vary with 
the concentration of the liquid sclerosing solution, the types of syringes, and the 
mode of pumping.68
iii)The double-syringe system (DSS) technique
The double-syringe  system version  is  defined for  3% polidocanol  solution,  two 
latex-free 10-mL syringes (one with rubber plunger) and a fixed liquid-to-air ratio of 
exactly 1:5 (one plus four). Pumping the contents of both syringes backward, 5 
times with additional pressure or 7 times without additional pressure, generates 
foam. This procedure gives small-bubbled viscous foam.
3.5.11 Procedure
Foam is injected into the vein to be obliterated under ultrasound guidance, either 
directly or via an intravenous catheter. Usually this is done proximal to distally, 
though the other way is also equally acceptable.   There should be a minimum 
distance of 10 cm from sapheno-femoral junction to the point of injection. The limb 
should  be  elevated  once  the  foam  has  been  injected.  The  foam  can  be 
manipulated using the probe to wherever it is needed. Once the foam reaches the 
sapheno femoral junction, compression is given using the probe for 10 minutes. 
Then  deep  veins  are  screened  for  any  foam  particle  and  if  present,  they  are 
washed off by alternative flexion-extension at ankle joint. Elastocrepe bandage or 
stockings is applied and the patient is asked to walk for atleast 30 minutes. This is 
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to improve deep venous circulation to wash away any foam that has entered the 
deep system. 
4.0 Materials and methods
4.1 Sample size and randomisation
Since there were no previous similar studies, it was planned to arbitrarily include 
60  patients  and  randomly  allocate  30  patients  each  to  surgery  and  foam 
sclerotherapy group. 
4.2 Inclusion criteria
All patients with symptomatic primary venous insufficiency of lower limbs, 
who were willing for definitive management with surgery and foam sclerotherapy, 
were included.
4.3 Exclusion criteria:
• Patients with a history or duplex finding of deep venous thrombosis
• Patients  who  had  already  undergone  surgery  for  superficial  venous 
insufficiency
• Patients not willing for randomization
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4.4 Informed consent
All  the  patients  were  explained  about  their  disease  and  treatment  options 
available. The complications and long term results of both the procedures were 
explained. Only those patients  who were willing for  random allocation to either 
surgery or foam sclerotherapy were included in the study.  Patients were free to 
withdraw from the study at any time.
4.5 Methodology
All  patients  presenting  with  features  of  venous  insufficiency  underwent  clinical 
examination  and  venous  duplex  examination.  Patients  who  were  willing  for 
definitive management were randomized into two groups – one for surgery and 
another for foam sclerotherapy.
4.6 Conventional Surgery
Trendelenburg’s operation, stripping of great saphenous vein, stab avulsion of pre-
marked  varicose  veins  with  or  without  sapheno-popliteal  junction  ligation  were 
done.
Postoperative pain was assessed with visual analog scoring system and analgesic 
requirement. Postoperative complications were noted.
Elastocrepebandage was applied continuosly for 3 days and during daytime for 6 
weeks postoperatively.
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Clinical assessment and duplex screening for recurrence was done at 3 months. 
Assessment was done using CEAP class and venous severity score. 
4.7 Ultrasound guided foam sclerotherapy
4.7.1 Technique of foam production (Tessari method)
Foam was prepared using two 10 ml syringes and a three way stop cock.  2 ml of 
3% Sodium tetra decyl sulphate and 8 ml of air were taken and about 20 passes 
were made between the two syringes. The stability of foam thus obtained was 2-3 
minutes.
4.7.2 Procedure
1) Venous network was mapped and drawn on skin and site of injection 
was chosen usually 10 cm below the knee.
2) A 24 gauge intravenous catheter was placed under ultrasound guidance 
into the vein to be obliterated.
3) Intravenous position is confirmed
4) Foam was prepared using Tessari method
5) Foam injected under ultrasound guidance and massaged with probe in 
the varicose network.
6) Sapheno-femoral  junction was compresses with  probe for 10 minutes 
when foam reached there.  
7) Deep veins screened for foam; if present, cleared with rapid ankle flexion 
and extension maneuvers.
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8) Elastocrepebandage  or  grade  2  compression  stockings  applied  for  3 
days continuously and then during daytime only for 6 weeks.
9) Walking for 30 minutes immediate post procedure and daily.
10)  Severity of pain and complications were noted.
11)  Surveillance with duplex examination was done at 1 week and injection 
done if necessary.
12)  After 3 months, clinical examination, duplex study and assessment of 
symptoms were done.  
4.8 Statistical Analysis
The results were tabulated on a spread sheet and statistical analysis was done 
using SPSS software with the help of bio-statistician.
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5.0 Results
5.1 Improvement in CEAP class
Group Parameter At Presentation At 3 months
Surgery Mean 4.30 3.00
Standard deviation 1.264 1.819
Foam 
Sclerotherapy
Mean 4.23 2.62
Standard deviation 1.382 1.781
In the surgery group the mean CEAP class improved from 4.3 to 3.0. In the foam 
sclerotherapy group the  mean CEAP class  improved from 4.23  to  2.62.  Using 
Mann-Whitney test,  there was no statistically significant  difference between the 
improvements seen in both the groups (p=0.235).
5.2 Improvement in Venous Severity Score (VSS)
Group Parameter At Presentation At 3 months
Surgery Mean 5.57 2.30
Standard deviation 3.730 2.409
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Foam 
Sclerotherapy
Mean 5.40 1.67
Standard deviation 3.379 1.516
In  the  surgery  group  the  mean  VSS improved  from 5.57  to  2.3.  In  the  foam 
sclerotherapy  group  the  mean  VSS  improved  from  5.4  to  1.67.  Using  Mann-
Whitney  test,  there  was  no  statistically  significant  difference  between  the 
improvements seen in both the groups (p=0.381).
5.3 Symptomatic Improvement
In  the  surgery  group  29  out  of  30  patients  i.e.,  96.7%  had  symptomatic 
improvement compared to 28 out of 30 patients i.e., 93.3% in sclerotherapy group. 
There is no statistical difference in the symptomatic improvement between the two 
groups (p=0.47).
5.4 Complications
Surgery
• Wound infection      –  2
• Wound dehiscence  –  1
• Bruising                   – 1
Foam sclerotherapy
• Skin necrosis          –  1
• Phlebitis                 –  2
• Staining                  – 1
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Complications in both the groups were minor and rates were similar.
5.5 Analgesic requirements
• Surgery: 
– All  patients  required  oral  analgesics.  In  addition,  60%  required 
injectable analgesic.
• UGS: 
– Only 20% of patients in foam sclerotherapy required any analgesic.
5.6 Cost of procedure
• Surgery: Approximately, Rs. 10,000
• UGS: Approximately, Rs. 1,500
5.7 Time to return to work
• Surgery: Average 7 days 
• UGS: Average < 1 day
5.8 Number of injections required for foam sclerotherapy
• 85% Single injection
• 15% Two injections
5.9 Time required to do the procedure
• 15 to 20 minutes for each sitting of sclerotherapy
• 45 to 75 minutes for surgery
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6.0 Pictures
6.1 Preparing foam by Tessari method
6.2 Puncturing great saphenous vein under ultrasound guidance
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6.3 Injection of foam into great saphenous vein
6.4 Venospasm after injection of foam
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 Great Saphenous vein-Pre and 
Post Injection
Before Injection After Injection
Vasospasm
6.5 Compression at the sapheno-femoral junction
6.6 Sapheno-femoral junction at 3 months
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Sapheno femoral junction 
at 3 months
CFV
GSV
SFJ
6.7 Exposure of sapheno-femoral junction
6.8 Cannulating great saphenous vein prior to stripping
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6.9 Applying Esmarch bandage to reduce blood loss
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6.10 Multiple stab avulsions of varicose veins
7.0 Graphs
7.1 Mean CEAP class at presentation and 3 months
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0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Surgery UGS
At presentation
At 3 months
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7.2 Mean Venous Severity Score at presentation and 3 months
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8.0 Discussion
Despite  the  high  prevalence  of  chronic  venous  insufficiency,  they  are  often 
neglected or inadequately managed. Though surgery has been the gold standard 
of treatment, it has not been able to achieve complete cure in all the patients. In 
the quest to find better treatments with lesser morbidity,  many newer modalities 
have  come into  vogue.  Of  all  these  foam  sclerotherapy  has  shown  promising 
results.  It  is  safe,  easy to perform and cheap, making it  ideal for  a developing 
country like ours.  
 
The  pre-procedure  epidemiological  characteristics,  CEAP  class  and  venous 
severity score were  similar  in both the groups.  There was no recanalisation of 
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superficial system at 3 months in both the groups, proving the efficacy of foam 
sclerotherapy  in  the  short  term.  The  improvement  in  CEAP class  and  venous 
severity scores was comparable in both the groups. D.G. Bountouroglou et al13,
Bergan et al 69, Pascarella et al 71 and Guex75 have reported similar improvements 
in their study. 
The number of injections required to obliterate great saphenous vein was one in 
85% of the patients. The remaining 15% required a second injection. 
A recent systematic review of foam sclerotherapy for varicose veins by  Jia  et al 
has concluded that  there is insufficient evidence to allow a meaningful comparison 
of the effectiveness of this treatment with that of other minimally invasive therapies 
or  surgery.  But  the  meta-analysis  for  complete  occlusion  suggests  that  foam 
sclerotherapy is less effective than surgery (relative risk - 0.86). 72
From our study we conclude that foam sclerotherapy can be considered a good 
alternative for surgery in terms of its efficacy in short term.
The complications that occurred in foam sclerotherapy were mostly in the early 
part. One patient developed skin necrosis due to accidental extravasation. As the 
learning curve improved the complications decreased.  Our complication rate was 
about 10%; there was no serious adverse event. The complication rates reported 
by other investigators were also low.69,73,74 In a series of 6,395 injections with foam 
by  Guex  et  al,  the  adverse  events  reported  were  less  than  0.4%.75 In  the 
systematic  review by  Jia  et  al72,  the  median  rates  of  serious  adverse  events, 
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including pulmonary embolism and deep vein thrombosis, were less than 1 per 
cent. The median rate of visual disturbance was 1.4 per cent, headache 4.2 per 
cent,  thrombophlebitis  4.7  per  cent,  matting/skin  staining/pigmentation  17.8 per 
cent and pain at the site of injection 25.6 per cent.72
Most of the patients undergoing foam sclerotherapy were able to continue working 
on  the  same  day  when  compared  to  surgery  group  in  which  2  to  3  days 
hospitalization and 3 to 5 days of leave from duty were needed. This definitely 
proves  the  minimal  morbidity  and  patient  friendliness  of  foam  sclerotherapy. 
Bergan et al also reported no disability down time in their initial experience of 322 
patients.69  Wright et al reported the time to return to work as ranging from 1 to 6 
weeks following surgery for varicose veins.70 In a randomized controlled trial by
D.G.  Bountouroglou  et  al,  the  median time  to  return  to  normal  activities  was 
significantly reduced in the  foam sclerotherapy group (2 days) compared to the 
surgical group (8 days)13 The median time of 2 days reported in this study was due 
to the addition of saphenofemoral ligation to foam sclerotherapy.
Foam sclerotherapy was about 6 times cheaper than surgery in our study.  The 
overall cost of the procedure in the sclerotherapy group (£672.97) was significantly 
less  compared  to  conventional  surgery  (£1120.64)  in  a  study  by  D.G. 
Bountouroglou  et  al.13  In  this  study,  foam  sclerotherapy  was  combined  with 
saphenofemoral ligation which may have increased the cost of procedure.
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The time required to do the procedure was also considerably shorter than surgery. 
It usually takes 15 to 20 minutes each session of foam sclerotherapy while surgery 
usually requires 45 to 75 minutes. In a similar study, the time taken to complete 
treatment was shorter in the foam sclerotherapy plus SFJ ligation group compared 
to conventional surgery: 45 vs. 85 min.13
 Moreover  foam  sclerotherapy  is  an  outpatient  procedure  with  no  need  for 
anaesthesia, thus reducing the burden of health care. 
We acknowledge that a small threat to validity (i.e., a bias) may exist in this study 
since the investigators were not blinded.
9.0 Conclusions
1. Obliteration of superficial venous system in short term (3 months) is similar 
in surgery and foam sclerotherapy.
2. Clinical  improvement  as  measured  by  CEAP class  and  venous  severity 
score are similar in both groups
3. Complications in both the groups are minor and relatively less frequent
4.  Foam sclerotherapy is less time consuming and less morbid than surgery
5.  Patients undergoing foam sclerotherapy returned to work earlier
6. Foam sclerotherapy is significantly cheaper than surgery.
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10 Clinical Significance and role for further trials
• Foam sclerotherapy is a safe, simple, cost effective treatment for varicose veins
• Foam sclerotherapy is a promising alternative to surgery in the management of 
chronic venous insufficiency
• Since the sample size is small  and follow up period is short,  long-term and 
large  scale  studies  have  to  be  done  before  foam  sclerotherapy  could  be 
considered  the  gold  standard  in  the  management  of  chronic  venous 
insufficiency
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Appendix 1
RANDOMIZED CONTROLLED STUDY COMPARING CONVENTIONAL 
SURGERY AND ULTRASOUND GUIDED FOAM SCLEROTHERAPY FOR 
PRIMARY SUPERFICIAL VENOUS INSUFFICIENCY
     PROFORMA FOR PATIENTS UNDERGOING ULTRASOUND GUIDED 
 FOAM SCLEROTHERAPY
Name:                                                               Age:                              Sex:  Male/ Female
Hospital No.:                                                     Serial No.:
Address:
Phone No.:
Date of Procedure:                                           Date of follow up:
CLINICAL ASSESSMENT:
CEAP CLINICAL CLASS:
At 
presentation
After 3 
months
6 months 12 
months
18 
months
24 
months
CEAP
Clinical Score
Ulcer size
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Clinical At presentation After  3 months
Right Left Right Left
No visible signs of venous disease               0
Telangiectasia or reticular                            1
Varicose veins                                              2
Edema                                                          3
Skin changes                                                4
Skin changes + healed ulcer                        5
Skin changes + active ulcer                         6
Asymptomatic                                             A
Symptomatic                                                S
CLINICAL SCORE
                   
At presentation After 3 months
Right Left Right Left
PAIN                                            None      0
                       Moderate, no analgesics      1
                  Severe, analgesics required      2
EDEMA                                       None      0
                                     Mild, moderate 1
                                                   Severe      2
VENOUS CLAUDICATION      None      0
                                      Mild, moderate     1
                                                    Severe     2
PIGMENTATION                        None     0
                                               Localized     1
                                               Extensive     2
LIPODERMATOSCLEROSIS    None     0
                                               Localized     1
                                               Extensive     2
ULCER, SIZE                              None     0
                                    < 2 cm diameter     1
                                     > 2cm diameter     2
ULCER, DURATION                  None     0
                                            < 3 months     1
                                            > 3 months     2
ULCER, RECURRENCE            None     0
                                                      Once     1
                                     More than once     2
ULCER, NUMBER                     None     0
                                                    Single     1
                                                 Multiple     2
TOTAL  CLINICAL SCORE
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PAIN SEVERITY SCORE:                                         Pre procedure     1st day        1 week
  
VENOUS DOPPLER FINDINGS:
At admission At 1 week After 3 months
DVT NA
SFJ(Size)
GSV(Calibre)
SPJ(Size)
Perforators 
(Number)
Deep Venous 
Reflux
Volume of foam injected:
COMPLICATIONS:
Complications Yes/No Description
Allergic reactions 
Cough 
Visual disturbances 
Tenderness
Haematoma
Hyperpigmentation
Ulcers / others
No. of sittings required for obliteration of GSV/SSV:
Time to return to work:
Total hospital cost:
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Appendix 2
INFORMED CONSENT DOCUMENT
Patient Information:
You have been diagnosed to have primary venous insufficiency of lower limbs. This is a 
condition in which the valves in the veins become leaky so that high pressure blood from 
deep veins enters the superficial veins. This causes varicose veins, skin changes, swelling of 
leg and ulceration, if left untreated.
At present there are two modalities of treatment available for this condition,  surgery and 
foam sclerotherapy. 
Surgery:  This is the routine treatment which is done for varicose veins. 
The procedure:  
   An incision (cut) is made at groin to find the junction of great saphenous (superficial) vein 
and  femoral  (deep)  vein  which  is  disconnected.  Some  of  the  tributaries  of  the  great 
saphenous vein will also be ligated. 
   The great saphenous vein is then stripped (removed) to just below the knee. Then removal 
of varicose veins in the lower  leg is done via multiple small cuts(avulsions).
Groin wound is closed with sutures and avulsion wounds heal without sutures.
At the end of the operation, compression bandages are applied to the leg to prevent bleeding 
and bruising. This operation usually takes 45 to 60 minutes for each leg.
   This is usually done under spinal anaesthesia in which an injection is given at your back 
which temporarily blocks your sensation below the waist.
  This procedure will be done by the consultant vascular surgeon/ general surgeon or surgical 
registrar. The surgeon who has seen you in the OPD and the one who performs the operation 
may not be the same. 
Serious or frequently occurring risks: 
• Removing varicose veins always produces some bruising and soreness. The severity of 
this depends on how many veins are removed. Sometimes, it can take several weeks for all 
the bruising to settle completely. 
• Because the main wound is in the groin, this area can become infected, which can usually 
be treated by a course of antibiotics. The same applies to other wounds on the leg.
•  Small  nerves  lying  next  to  the veins  can be disturbed,  which can lead  to  patches  of 
numbness in the lower leg and foot in 10 to 20% of patients. This usually resolves over the 
first year after surgery but occasionally, it is permanent. 
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• Rarely, a deep vein thrombosis (blood clot; DVT) can occur in the deeper veins of the leg 
and, occasionally,  this can lead to a pulmonary embolus (blood clot to the lung). Blood 
clots on the lung can be fatal. Thrombosis occurs in less than 0.1% of patients. 
• Varicose veins can grow back (recur), usually by regrowth of the veins. After 5 years, 
10% of patients can have this recurrence. 
Ultrasound guided foam sclerotherapy:
The procedure: 
Ultrasound guided sclerotherapy usually involves injection of foam into the saphenous vein 
-  most  commonly  from  the  groin  to  the  knee.  This  procedure  will  be  done  by  a 
sclerotherapist radiologist. 
No anaesthesia will be given. After the procedure, an elastocrepe bandage is worn for 72 
hours continuously and 6 weeks during the day only. A 60 minute daily walk is mandatory 
in first week. 
You will be reviewed one week after the initial sclerotherapy and if necessary you may 
need to undergo one more injection.
The most common side effects experienced with UGS are:
1. Blood trapping: In large varicosities some blood can be trapped inside the vein. The 
body takes two to three months to break down and reabsorb the blood. In the meantime the 
vein can feel hard and can look lumpy. Occasionally the trapped blood can make the vein 
feel tender. This is usually transient but if it persists it may be better to have the blood 
removed - this is best done four to six weeks after treatment. 
2.  Hyperpigmentation:  Approximately  10% of  patients  who  undergo  UGS notice  light 
brown streaks over the treated veins after treatment. 
3. Phlebitis: In about 1% of cases.
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Rare possible side effects after UGS include: 
1. Ulcers: They consist of a small ulceration at the injection site that heals slowly over one 
to two months.
2. Allergic reactions: Very rarely a patient may have an allergic reaction to the sclerosant.
3. Transient visual disturbance:  This is experienced as black areas in the field of vision. 
They may last for a few minutes. It occurs in less than 0.3% of patients.
4. Telangiectatic matting: This refers to the development of new tiny blood vessels around 
the treated vessel and occurs in less than 2% of patients
5. Ankle swelling: Ankle swelling may occur after treatment of blood vessels in the foot or 
ankle.  It  usually  resolves  in  a  few  days  and  is  lessened  by  wearing  the  prescribed 
compression hosiery.
6. Deep Vein Thrombosis (DVT): This is a very rare complication, seen in approximately 1 
out of every 7000 patients treated for varicose veins greater than 3 to 4mm in diameter. The 
possible dangers of DVT include the possibility of a pulmonary embolus (a blood clot to 
the lungs) and postphlebitis syndrome, in which the blood clot is not carried out of the legs, 
resulting in permanent swelling of the legs.
7. Risk of stroke: One case of transient monoparesis (weakness in one limb) due to foam 
embolization has been reported. This was due to an abnormal communication between right 
and  left  side  of  the heart  (patent  foramen  ovale)  which  is  present  in  upto 27% of  the 
population.
The recurrence rates after UGS are similar to but little higher than surgery.
   If you are willing to participate in our study comparing surgery with foam sclerotherapy for 
the treatment of varicose veins, you will be randomly assigned to one of the treatment groups 
i.e. you will have equal chance of receiving either one of the treatments.
   It is not compulsory to participate in this study.
   If you want one of the treatments specifically, you will not be part of our study but will 
receive the best of our care in the required treatment.
   You may choose to withdraw from our study at any time but will still get the appropriate 
treatment.
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CONSENT: 
      I have been informed to have primary venous insufficiency of my right and / or left lower 
limb(s) and the need for definitive management with surgery or foam sclerotherapy,  in a 
language which I can understand.
I agree to participate in the study comparing surgery and foam sclerotherapy voluntarily.
I am willing to undergo either surgery or foam sclerotherapy according to the randomization. 
I am fully aware of the complications of both the procedures
I understand that I can choose any one of two procedures according to my wish and still 
receive the best care but will not be part of the study in that case.
 I understand that the doctor whom I consulted initially may not necessarily be operating / 
doing sclerotherapy on me and being a teaching institution, doctors in surgical training may 
also be part of the team.
 I may choose to withdraw from this study at any time without any negative consequences. 
Date:                                                                                  (Patient’s name and signature)
                                                                               (Doctor’s name and signature)
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